Press Releases
The latest announcements from Protagen, from our research programs to commercialization and partnerships—scroll down to find out more about what’s been happening in Dortmund and beyond.
For more information on any of the news items featured on this page, please contact:
Contact
Dr Georg Lautscham
CEO
bd@protagen.com
T +49 231 9742 6300
Media Enquiries
Dr Clare Russell
Managing Director, BioStrata, UK
crussell@biostratamarketing.com
T +44 1223 627121
The EORTC Brain Tumor Group and Protagen AG announce their collaboration to investigate the immuno-competence of long-term Glioblastoma survivors
The European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group and Protagen AG today announced a collaboration to utilize Protagen’s Cancer Immunotherapy Array to identify autoantibody biomarkers that investigate the immunological...
read moreThe National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG extend their collaboration to investigate the immuno-competence of urothelial cancer patients receiving immunotherapy
The National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG today announced a collaboration to utilize Protagen’s Cancer Immunotherapy Array to identify biomarkers that predict therapeutic response and the incidence of immune-related adverse...
read moreNEC Laboratories Europe GmbH, the National Center for Tumor Diseases and Protagen AG collaborate to improve information integration and artificial intelligence for better therapy decisions in Immuno-Oncology
Protagen AG, the National Center for Tumor Diseases (NCT) and NEC Laboratories Europe GmbH have today announced a collaboration to improve the in silico prediction of immunotherapy response in malignant melanoma. Cancer immunotherapy, e.g. by Checkpoint...
read moreProtagen AG collaborates with UCSF to study better immuno-profiling of cancer patients receiving immunotherapy
Protagen AG has today announced the start of a collaboration with the University of California, San Francisco (UCSF) to utilize Protagen’s SeroTag® technology to investigate the immuno-profiling of prostate cancer patients treated with checkpoint...
read moreGustave Roussy and Protagen AG collaborate to improve the risk profiling of cancer patients undergoing immunotherapy
Protagen AG and Gustave Roussy have today announced the start of a collaboration to utilize Protagen’s SeroTag® technology to help identify biomarkers that predict and monitor immune-related adverse events (irAEs) in cancer patients treated with checkpoint...
read moreProtagen AG joins forces with the U.S. National Cancer Institute to answer pressing questions in immuno-oncology
Protagen AG has executed a Material Transfer Agreement with the National Cancer Institute (NCI) under which the parties will utilize Protagen's SeroTag® immune system profiling technology to identify biomarkers that predict therapy responsiveness, to...
read moreThe German National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG Investigate Responsiveness to Checkpoint Inhibitors in Melanoma
The German National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG today announced a collaboration to utilize Protagen’s SeroTag® technology to identify biomarkers that predict therapy responsiveness and the detection of immune-related adverse...
read moreProtagen AG successfully joined forces with Novartis to support Clinical Development of a Novel Compound in an Autoimmune Indication
PROTAGEN AG, a leading provider of pharma development services, novel diagnostic tests and companion diagnostics in the fields of immuno-oncology and autoimmune disease, today announced the successful completion of a collaboration agreement with Novartis...
read morePROTAGEN Launches NavigAID Assay to Support Clinical Drug Development for Autoimmune Diseases
Systemic Sclerosis (SSc) Disease Stratification Assay expands the NavigAID product line across multiple potential targeted therapies and disease states Protagen AG, a leading provider of pharma development services, companion diagnostics and novel...
read moreProtagen AG Announces Changes to Their Management Board
Protagen AG. a leading provider of pharma development services, novel diagnostic tests and companion diagnostics in the fields of immuno-oncology and autoimmune disease, today announced changes to their Management Board. Dr. Georg Lautscham will join the...
read more
Leadership
Protagen’s corporate leadership team combines over 40 years of commercial expertise and experience within the biotechnology industry, with a background spanning immunology, oncology, biomarker discovery and more.
Scientific Advisory Board
Protagen is currently setting up an international scientific advisory board with key opinion leaders from the immuno-oncology and autoimmune disease fields. These expert panels will support our efforts in engaging with the medical and scientific community to develop products that are aimed at market needs.
Investors
Protagen has a number of established and committed investors, but is always looking at entering into new partnerships to help progress its research and commercialization efforts. If you are interested in investing in the company, please contact us.
Careers
Protagen is always looking to expand its talented and experienced team. For information on some of the job roles available, simply click below.
Our Company
Protagen is dedicated to the development of powerful diagnostic tools that aid successful therapeutic development and facilitate improved treatment strategies in the areas of autoimmune disease and immuno-oncology.
Stratified News
Here you will find our quarterly newsletter, “Stratified News from Dortmund”. With our newsletter we intend to regularly update you on developments at Protagen in a fresh and colorful format and we hope that you like it.
Get in touch
Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.
Copyright © 1997-2018
Protagen AG, Dortmund, Germany
Useful Links
